These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa. Bourdin M; Perrotin D; Mathieu O; Herve T; Depasse F; Lu G; Conley PB; Contant G Int J Lab Hematol; 2021 Aug; 43(4):795-801. PubMed ID: 34092030 [TBL] [Abstract][Full Text] [Related]
8. Andexanet Alfa: First Global Approval. Heo YA Drugs; 2018 Jul; 78(10):1049-1055. PubMed ID: 29926311 [TBL] [Abstract][Full Text] [Related]
10. Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent. Powell J; Taylor J; Garland SG Ann Pharmacother; 2019 Sep; 53(9):940-946. PubMed ID: 30813754 [No Abstract] [Full Text] [Related]
11. Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation. Ghadimi K; Dombrowski KE; Levy JH; Welsby IJ Expert Rev Hematol; 2016; 9(2):115-22. PubMed ID: 26686866 [TBL] [Abstract][Full Text] [Related]
12. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050 [TBL] [Abstract][Full Text] [Related]
13. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Lu G; Conley PB; Leeds JM; Karbarz MJ; Levy GG; Mathur VS; Castillo J; Crowther M; Curnutte JT Blood Adv; 2020 Feb; 4(4):728-739. PubMed ID: 32092140 [TBL] [Abstract][Full Text] [Related]
14. A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA). Rogers KC; Finks SW Am J Med; 2019 Jan; 132(1):38-41. PubMed ID: 30053385 [TBL] [Abstract][Full Text] [Related]
15. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. Lester PA; Coleman DM; Diaz JA; Jackson TO; Hawley AE; Mathues AR; Grant BT; Knabb RM; Ramacciotti E; Frost CE; Song Y; Wakefield TW; Myers DD Arterioscler Thromb Vasc Biol; 2017 May; 37(5):942-948. PubMed ID: 28232327 [TBL] [Abstract][Full Text] [Related]
16. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies. Escolar G; Diaz-Ricart M; Arellano-Rodrigo E Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000 [TBL] [Abstract][Full Text] [Related]
17. Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal. Maragkos GA; Nelton EB; Richter S; Stippler M World Neurosurg; 2020 Oct; 142():e95-e100. PubMed ID: 32561488 [TBL] [Abstract][Full Text] [Related]
18. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures. Bradshaw PG; Keegan SP; Droege ME; Dykes NJH; Ernst NE; Foertsch MJ; Makley AT; Mueller EW; Philpott CD; Srinivasan V; Winter JB; Goodman MD; Droege CA Pharmacotherapy; 2022 Oct; 42(10):780-791. PubMed ID: 36073083 [TBL] [Abstract][Full Text] [Related]